Natural Antimicrobial Peptide Protects Against Skin Wart Virus by Boosting Immune Response
Mice lacking the antimicrobial peptide CRAMP (the mouse equivalent of human LL-37) developed extensive skin warts after papillomavirus infection, showing that cathelicidins protect against HPV primarily through immune modulation rather than direct antiviral action.
Quick Facts
What This Study Found
CRAMP-deficient mice developed robust skin papillomas after papillomavirus infection while wild-type mice did not. Protection was primarily immune-mediated: CRAMP-deficient mice showed reduced CD4+ and CD8+ T cells and lacked virus-specific neutralizing antibodies.
Key Numbers
Robust papillomas in CRAMP-deficient mice; none in wild-type; reduced CD4+ and CD8+ T cells; no neutralizing antibodies without CRAMP
How They Did This
Animal study. CRAMP-deficient and wild-type C57BL/6J mice were treated with cyclosporine A and experimentally infected with mouse papillomavirus 1. Papilloma development, immune cell counts, neutralizing antibody levels, and direct antiviral effects of synthetic CRAMP were analyzed.
Why This Research Matters
This is the first in vivo evidence that cathelicidin antimicrobial peptides protect against papillomavirus infection, primarily by enhancing immune responses. This could inform new prevention or treatment strategies for HPV-related diseases in humans.
The Bigger Picture
LL-37/cathelicidins are increasingly recognized as immune regulators beyond simple antimicrobial agents. This study adds HPV defense to their repertoire and suggests that maintaining cathelicidin levels could be relevant for people at risk of HPV-related conditions.
What This Study Doesn't Tell Us
Mouse model with cyclosporine A immunosuppression, which may amplify cathelicidin's protective role. Mouse papillomavirus differs from human HPV. CRAMP is not identical to human LL-37. Sample size not reported.
Questions This Raises
- ?Could LL-37 supplementation or upregulation help prevent or treat HPV infections in humans?
- ?Do people with naturally lower LL-37 levels have higher susceptibility to persistent HPV infections?
- ?Would topical cathelicidin application be effective against skin or genital warts?
Trust & Context
- Key Stat:
- First in vivo HPV protection CRAMP is the first cathelicidin antimicrobial peptide shown to protect against papillomavirus infection in a living animal model
- Evidence Grade:
- Moderate evidence: controlled animal study demonstrating a clear mechanism, but uses an immunosuppressed mouse model and mouse papillomavirus rather than human HPV.
- Study Age:
- Published in 2021. Research on cathelicidins and viral defense continues with increasing interest in their immune-modulatory roles.
- Original Title:
- Deficiency of Cathelicidin-related Antimicrobial Peptide Promotes Skin Papillomatosis in Mus musculus Papillomavirus 1-infected Mice.
- Published In:
- Acta dermato-venereologica, 101(1), adv00367 (2021)
- Authors:
- Dorfer, Sonja, Strasser, Katharina, Reipert, Siegfried, Fischer, Michael B, Shafti-Keramat, Saeed, Bonelli, Michael, Schröckenfuchs, Georg, Bauer, Wolfgang, Kancz, Stefanie, Müller, Lena, Handisurya, Alessandra
- Database ID:
- RPEP-05350
Evidence Hierarchy
Frequently Asked Questions
What is CRAMP and how does it relate to LL-37?
CRAMP is the mouse version of the human antimicrobial peptide LL-37 (both are cathelicidins). They serve similar immune defense functions, so studying CRAMP in mice helps researchers understand how LL-37 might work in humans.
Could this help with HPV treatment in humans?
Potentially. If human LL-37 has similar protective effects against HPV, strategies to boost cathelicidin levels (such as vitamin D supplementation, which induces LL-37 production) could complement existing HPV prevention approaches.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05350APA
Dorfer, Sonja; Strasser, Katharina; Reipert, Siegfried; Fischer, Michael B; Shafti-Keramat, Saeed; Bonelli, Michael; Schröckenfuchs, Georg; Bauer, Wolfgang; Kancz, Stefanie; Müller, Lena; Handisurya, Alessandra. (2021). Deficiency of Cathelicidin-related Antimicrobial Peptide Promotes Skin Papillomatosis in Mus musculus Papillomavirus 1-infected Mice.. Acta dermato-venereologica, 101(1), adv00367. https://doi.org/10.2340/00015555-3733
MLA
Dorfer, Sonja, et al. "Deficiency of Cathelicidin-related Antimicrobial Peptide Promotes Skin Papillomatosis in Mus musculus Papillomavirus 1-infected Mice.." Acta dermato-venereologica, 2021. https://doi.org/10.2340/00015555-3733
RethinkPeptides
RethinkPeptides Research Database. "Deficiency of Cathelicidin-related Antimicrobial Peptide Pro..." RPEP-05350. Retrieved from https://rethinkpeptides.com/research/dorfer-2021-deficiency-of-cathelicidinrelated-antimicrobial
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.